For the quarter ending 2026-03-31, ALAB had -$19,327K decrease in cash & cash equivalents over the period. $67,012K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 308,361 | - | 230,575 | 191,925 |
| Cost of revenue | 73,220 | - | 54,763 | 46,362 |
| Stock-based compensation | -27,067 | - | 40,360 | 35,121 |
| Personnel-related expenses | 63,305 | - | 52,892 | 43,843 |
| Other segment items | 43,112 | - | -8,554 | 15,380 |
| Net income | 80,310 | 44,982 | 91,114 | 51,219 |
| Stock-based compensation | 48,913 | 41,374 | 40,739 | 35,474 |
| Depreciation and amortization | 3,710 | 2,846 | 1,466 | 2,517 |
| Non-cash operating lease expense | 1,177 | 643 | 768 | 826 |
| Warrants contra revenue | 2,097 | 1,498 | 1,880 | 1,762 |
| Accretion of discounts on marketable securities | 1,202 | 1,654 | 1,789 | 1,947 |
| Other, net | 1,313 | 1,472 | 503 | -1,759 |
| Accounts receivable, net | 51,789 | 40,254 | 18,580 | -45,459 |
| Inventory | -346 | 5,844 | -7,471 | 7,790 |
| Prepaid expenses and other assets | -13,889 | -23,003 | 38,286 | 3,979 |
| Accounts payable | -699 | 15,282 | -5,695 | 2,381 |
| Accrued expenses and other liabilities | -20,841 | 16,394 | 968 | 10,084 |
| Operating lease liability | - | -1,533 | -1,382 | -1,274 |
| Net cash provided by operating activities | 74,598 | 95,265 | 78,171 | 135,366 |
| Purchases of property and equipment | 7,586 | 18,689 | 12,293 | 2,023 |
| Purchases of marketable securities | 156,628 | 193,321 | 259,750 | 213,861 |
| Sales and maturities of marketable securities | 137,756 | 168,005 | 171,498 | 152,191 |
| Payments for business combinations, net of cash acquired | 65,049 | 28,786 | - | - |
| Other investing activities | 2,500 | 0 | 500 | - |
| Net cash used in investing activities | -94,007 | -72,791 | -101,045 | -63,693 |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | - | 0 | 0 | 0 |
| Payment of deferred offering costs | - | 0 | 0 | 0 |
| Proceeds from employee stock purchase plan | - | 3,633 | 0 | 4,345 |
| Tax withholding related to net share settlements of restricted stock units | - | 0 | 0 | 0 |
| Repurchase of common stock upon termination | - | 0 | - | - |
| Proceeds from exercises of stock options | 82 | 95 | 952 | 392 |
| Net cash provided by financing activities | 82 | 3,728 | 952 | 4,737 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -19,327 | 26,202 | -21,922 | 76,410 |
| Beginning of the period | 167,684 | -61,438 | -83,360 | 80,044 |
| End of the period | 148,357 | 26,202 | -21,922 | 163,404 |
Astera Labs, Inc. (ALAB)
Astera Labs, Inc. (ALAB)